NCT03672188View on ClinicalTrials.gov

Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

September 3, 2020

Study Completion Date

September 3, 2020

Conditions
Chronic Hepatitis B
Interventions
DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

DRUG

Placebo

Sterile normal saline (0.9% NaCl) given by subcutaneous injection

Trial Locations (14)

1010

Investigative Site, Auckland

2025

Investigative Site, Auckland

3065

Investigative Site, Fitzroy

3168

Investigative Site, Clayton

4575

Investigative Site, Birtinya

10330

Investigative Site, Bangkok

10400

Investigative Site, Bangkok

10700

Investigative Site, Bangkok

40002

Investigative Site, Khon Kaen

49241

Investigative Site, Busan

90110

Investigative Site, Hat Yai

Unknown

Investigative Site, Hong Kong

03080

Investigative Site, Seoul

05505

Investigative Site, Seoul

Sponsors

Collaborators (1)

Alnylam Pharmaceuticals
All Listed Sponsors
collaborator

Alnylam Pharmaceuticals

INDUSTRY

lead

Vir Biotechnology, Inc.

INDUSTRY